MEDIVATION INC's ticker is MDVN and the CUSIP is 58501N101. A total of 365 filers reported holding MEDIVATION INC in Q1 2016. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $27,762,000 | +48.1% | 460,400 | +8.3% | 0.04% | +32.4% |
| Q1 2016 | $18,742,000 | +30.6% | 425,300 | +43.3% | 0.03% | -2.9% |
| Q4 2015 | $14,347,000 | +20.2% | 296,800 | +5.7% | 0.04% | +12.9% |
| Q3 2015 | $11,934,000 | -17.1% | 280,800 | +122.7% | 0.03% | -16.2% |
| Q2 2015 | $14,401,000 | -5.7% | 126,100 | +6.6% | 0.04% | -9.8% |
| Q1 2015 | $15,269,000 | +114.7% | 118,300 | +65.7% | 0.04% | +51.9% |
| Q4 2014 | $7,112,000 | -14.7% | 71,400 | -15.3% | 0.03% | -15.6% |
| Q3 2014 | $8,335,000 | +26.3% | 84,300 | -1.5% | 0.03% | +33.3% |
| Q2 2014 | $6,598,000 | +20.3% | 85,600 | +0.5% | 0.02% | +9.1% |
| Q1 2014 | $5,484,000 | +33.2% | 85,200 | +32.1% | 0.02% | +37.5% |
| Q4 2013 | $4,116,000 | +6.5% | 64,500 | 0.0% | 0.02% | 0.0% |
| Q3 2013 | $3,866,000 | +16.2% | 64,500 | -4.6% | 0.02% | +6.7% |
| Q2 2013 | $3,326,000 | – | 67,600 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 2,484,101 | $158,535,000 | 79.84% |
| Cormorant Asset Management, LP | 546,900 | $34,903,000 | 10.13% |
| BB BIOTECH AG | 1,479,706 | $94,435,000 | 5.04% |
| PFM Health Sciences, LP | 2,719,859 | $173,581,000 | 3.49% |
| Partner Investment Management, L.P. | 219,981 | $14,039,000 | 3.19% |
| Orbimed Advisors | 3,123,500 | $199,342,000 | 2.93% |
| Antipodean Advisors LLC | 525,000 | $33,506,000 | 2.90% |
| Eventide Asset Management | 134,800 | $8,603,000 | 2.65% |
| Bain Capital Public Equity Management, LLC | 1,428,117 | $91,142,000 | 2.58% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 257,055 | $16,405,000 | 2.52% |